A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia

Trial Profile

A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Gelsolin (Primary)
  • Indications Community-acquired pneumonia
  • Focus Adverse reactions; Biomarker
  • Sponsors BioAegis Therapeutics
  • Most Recent Events

    • 08 Mar 2018 Status changed from planning to not yet recruiting.
    • 17 Apr 2015 New trial record
    • 15 Apr 2015 BioAegis Therapeutics has received regulatory advice from European authorities which support plans to initiate this trial, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top